Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

NCT00802906 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Central Serous Chorioretinopathy

Interventions

DEVICE: subthreshold micropulselaser
DRUG: bevacizumab

Sponsor

Johann Wolfgang Goethe University Hospital